Visus Therapeutics, Inc.

📍 Seattle, United States🗓 Founded 2019👥 40 employees💰 Last funded 2021
Biotechnology Research🌐 visustx.com
Website LinkedIn
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Netherlands
1
Switzerland
1
Frequently asked questions
Who invested in Visus Therapeutics, Inc.?
Visus Therapeutics, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Visus Therapeutics, Inc. last raise funding?
The most recent investment in Visus Therapeutics, Inc. recorded on gritt.io was in 2021.
When was Visus Therapeutics, Inc. founded?
Visus Therapeutics, Inc. was founded in 2019.
What industry is Visus Therapeutics, Inc. in?
Visus Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Visus Therapeutics, Inc. based?
Visus Therapeutics, Inc. is headquartered in Seattle, United States.